Measurement of (18)F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model

PURPOSE: Treatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab. Size measurements are inadequate to assess treatment response to these agents, and newer response assessment criteria are needed. We aimed to evaluate (18)F-FDG PET-derived texture param...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashir, Usman, Weeks, Amanda, Goda, Jayant S., Siddique, Muhammad, Goh, Vicky, Cook, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553522/
https://www.ncbi.nlm.nih.gov/pubmed/30893213
http://dx.doi.org/10.1097/MNM.0000000000000992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553522/
https://www.ncbi.nlm.nih.gov/pubmed/30893213
http://dx.doi.org/10.1097/MNM.0000000000000992

Ejemplares similares